Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349222 | 0.81 | GRM5 (0.54) | GRM5CYP11B2 | |
| SCHEMBL15341902 | 0.79 | GRM5 (0.46) | GRM5CYP11B2TDP1IRAK4CYP11B1 | |
| SCHEMBL46326 | 0.79 | GRM5 (0.57) | GRM5CYP11B2IRAK4CYP11B1KDM4E | |
| SCHEMBL15520747 | 0.78 | GRM5 (0.56) | GRM5CYP11B2IRAK4CYP11B1MGLL | |
| SCHEMBL18307164 | 0.78 | GRM5 (0.56) | GRM5CYP11B2IRAK4CYP11B1KDM4E | |
| SCHEMBL1053384 | 0.78 | GRM5 (0.56) | GRM5CYP11B2IRAK4CYP11B1KDM4E | |
| SCHEMBL2398608 | 0.78 | GRM5 (0.56) | GRM5CYP11B2IRAK4CYP11B1KDM4E | |
| Hydrochloric Acid SCHEMBL23168041 | 0.76 | GRM5 (0.55) | GRM5CYP11B2IRAK4CYP11B1KDM4E | |
| SCHEMBL2459914 | 0.75 | GRM5 (0.53) | GRM5CYP11B2IRAK4CYP11B1KDM4E | |
| SCHEMBL21863669 | 0.75 | GRM5 (0.53) | GRM5CYP11B2IRAK4CYP11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-9846160-B2 | Ganglioside GD2 as a marker and target on cancer stem cells | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-12-19 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130190309-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2013-07-25 | — | — | US | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090270382-A1 | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270382-A1 | Soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, LTA4H | GRM5 4218/4885CYP11B2 1507/4885TDP1 1149/4885 |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | GRM5 2007/4885CYP11B2 490/4885TDP1 777/4885 |
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | GRM5 1699/4885CYP11B2 823/4885TDP1 733/4885 |
| US-20130190309-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 1532/4885CYP11B2 490/4885TDP1 1672/4885 |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 2298/4885CYP11B2 108/4885TDP1 950/4885 |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 1760/4885CYP11B2 483/4885TDP1 868/4885 |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | GRM5 1999/4885CYP11B2 416/4885TDP1 638/4885 |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | GRM5 2744/4885CYP11B2 355/4885TDP1 1438/4885 |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | GRM5 3167/4885CYP11B2 664/4885TDP1 1272/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GRM5 130/4885CYP11B2 1907/4885TDP1 1309/4885 |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | GRM5 1699/4885CYP11B2 738/4885TDP1 762/4885 |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 1808/4885CYP11B2 65/4885TDP1 1091/4885 |
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | GRM5 2224/4885CYP11B2 698/4885TDP1 747/4885 |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 1685/4885CYP11B2 344/4885TDP1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.